CAS: 41085-99-8; 1,1'-Dioctadecyl-3,3,3',3'-Tetramethylindocarbocyanine Perchlorate

📜1,1'-Dioctadecyl-3,3,3',3'-Tetramethylindolenium Carbocyanine Iodide置于lithium Perchlorate体系中,用 氯仿,丙酮 作为反应溶剂,以90 %的收率获得产物1,1'-双十八烷基-3,3,3',3'-四甲基吲哚菁高氯酸盐
参考文献:一种细胞膜橙色荧光染料dil的制备方法
标题:一种细胞膜橙色荧光染料dil的制备方法
摘要:本发明涉及医药染料领域,尤其是一种细胞膜橙色荧光染料dil的制备方法,以2,3,3‑三甲基‑3H‑吲哚和碘代十八烷为原料,经取代,缩合和盐置换等反应制得目标化合物dil.以三步串联反应制得dil,攻克了dir至dil的合成路线,其制备成本低廉,显著优于现有产品售价,有望降低相关科研及应用领域的投入成本;采用本制备方法产品操作简单,原料易得而且收率高,总收率达到43‑50%,并经过验证,可以实现规模放大;本发明均采用安全可控条件进行合成,成本低廉,合成路线较短,使用的原料简单易得,使制备工艺更不受限制,并且已验证其规模生产,表明其易于工业化生产潜力.

专利信息

专利号:WO-2024220674-A1
优先权日:2023-04-18
标题:Timescale-guided microfluidic synthesis of polyphenol-iron iii network nanocapsules of hydrophobic drugs
发明人：YEO YOON; HAN BUMSOO; SHEN YINGNAN
权利人:PURDUE RESEARCH FOUNDATION
摘要:A scalable method of continuous microfluidic synthesis of tannic acid-iron III (TA-FeIII) network (TFN) nanocapsules of a hydrophobic drug; a scalable method of continuous microfluidic synthesis of epigallocatechin-3-gallate iron III (EGCG-FeIII) network, (EFN) nanocapsules; hydrophobic drug nanocapsules synthesized in accordance with the method; and a method of administering a hydrophobic drug to a patient in need thereof by administering to the patient the hydrophobic drug nanocapsules.

专利号:US-2025205158-A1
优先权日:2023-12-26
标 题 :Biodegradable lipids and formulations for delivery of mrna
发明人：ANDERSON DANIEL GRIFFITH; RUDRA ARNAB; GUPTA AKASH; REED KAELAN
权利人:MASSACHUSETTS INST TECHNOLOGY; CHILDRENS MEDICAL CENTER
摘要:Provided herein are compounds, such as compounds of Formulae (I), (I′), (XI), (XII), and (XIII), and pharmaceutically acceptable salts, solvates, tautomers, stereoisomers, and isotopically labeled derivatives thereof, and compositions, methods, uses, and kits thereof. The compounds provided herein are lipids useful for delivery of agents, including polynucleotides such as mRNA, for the treatment and/or prevention of various diseases and conditions (e.g., genetic diseases, proliferative diseases, hematological diseases, neurological diseases, liver diseases, spleen diseases, lung diseases, painful conditions, psychiatric disorders, musculoskeletal diseases, metabolic disorders, inflammatory diseases, and autoimmune diseases). Also provided herein are methods of synthesis of compounds of Formulae (I′), (XI), (XII), (XIII), and (VIII).

专利号:US-2022218614-A1
优先权日:2020-12-04
标 题 :Ionizable cationic lipids and lipid nanoparticles, and methods of synthesis and use thereof
发明人：ALI MIR; BOESCH AUSTIN WAYNE; DRUMMOND DARYL CLARK; KUHLMAN WILLIAM; NIELSEN ULRIK
权利人:TIDAL THERAPEUTICS INC
摘要:Provided are ionizable cationic lipids and lipid nanoparticles for the delivery of nucleic acids to cells (e.g., immune cells), and methods of making and using such lipids and targeted lipid nanoparticles.

专利号:WO-2024040267-A2
优先权日:2022-08-19
标题 :Direct synthesis of n-(3-substituted-chroman-4-yl)-7h- pyrrolo[2,3-d]pyrimidin-4-amines and derivatives thereof

专利号:US-2025115956-A1
优先权日:2021-06-23
标题 :Methods and compositions for nucleic acid sequencing
发明人：WHITEFORD NAVA EDMOND
权利人:Nanogami GmbH
摘要:The present disclosure in some aspects relates to real-time nucleic acid sequencing comprising one or more detectable label deactivation steps, such as stochastic photobleaching that occurs during sequential nucleotide incorporation in a sequencing-by-synthesis reaction. Deactivation of the detectable label(s) of a particular labeled nucleotide may occur prior to, during, and/or after the incorporation of the next nucleotide, for instance, a labeled nucleotide that forms a phosphodiester bond with the particular labeled nucleotide. Also described herein are methods of analyzing sequencing data obtained from the sequencing methods.

专利号:US-2025109436-A1
优先权日:2022-02-08
标 题 :Methods, compositions, and systems for long read single molecule sequencing
发明人：WHITEFORD NAVA EDMOND
权利人:RETICULA INC
摘要:The present disclosure in some aspects relates to real-time nucleic acid sequencing comprising i) cluster decimation by deactivating some strands in a cluster, ii) bringing the non-deactivated strands in the cluster out of sync with each other during sequencing, and/or iii) one or more detectable label deactivation steps, such as stochastic photobleaching that occurs during sequential nucleotide incorporation in a sequencing-by-synthesis reaction. Deactivation of the detectable label(s) of a particular labeled nucleotide may occur prior to, during, and/or after the incorporation of the next nucleotide, for instance, a labeled nucleotide that forms a phosphodiester bond with the particular labeled nucleotide. Also described herein are methods of analyzing sequencing data obtained from the sequencing methods.